PACB · Pacific Biosciences Of California, Inc.
Market Cap
$397.86M
Shares
310.83M
PACB metrics
62 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.32
Market cap
$397.86M
Price action
19 metricsPrice change (1W)
-15.8%
Price change (30D)
-9.9%
Price change (3M)
-19.0%
Price change (6M)
-15.8%
Price change (YTD)
-31.6%
Price change (1Y)
-2.3%
Trailing year
Price change (5Y)
-96.0%
52-week high
$2.67
52-week low
$1.11
Change from 52-week high
-52.1%
Change from 52-week low
+15.3%
Annualized volatility
88.8%
Beta
2.5
RSI (14D)
46.4
Price vs SMA 50
-9.2%
Price vs SMA 200
-22.0%
Avg volume (3M)
6.66M
Relative volume
0.9
Average dollar volume
$9.39M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
310.83M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 40.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-33.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
25.6×
reciprocal yield 3.9%
EV / revenue historical average (5Y)
22.1×
reciprocal yield 4.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-05
Profitability
9 metricsGross margin
36.4%
Operating margin
-83.5%
Trailing 12 months
Net margin
-82.5%
Gross profit (TTM)
$57.95M
Operating profit (TTM)
−$133.04M
Net income (TTM)
−$131.39M
Trailing 12 months
Diluted EPS (TTM)
$-0.41
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-1.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$159.27M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+15.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-17.5%
Debt / equity
—
Current ratio
4.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.0
Interest coverage
-18.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$61.00M
Total assets
$751.85M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$118.05M
Capital expenditures (TTM)
—
R&D (TTM)
$88.36M
SG&A (TTM)
$129.70M
Stock compensation (TTM)
$34.29M
R&D / revenue
55.5%
Stock compensation / revenue
21.5%
Ownership (13F)
3 metrics13F filers
222
13F filer change QoQ
-10
Institutional ownership
61.8%
Short interest
3 metricsShort interest
17.2%
Latest settlement · 6.6 days to cover
Days to cover
6.6d
Short-squeeze score
77 / 100
Insider activity
2 metricsNet insider buying (90D)
−$30,409
Insider-sentiment score
53 / 100
Risk flags
1 metricsGoing concern
—